Severe COVID-19 infection may occur in 1 out of 5 people, claimed by a new study. According to The New York Times' latest report, one of the underlying health conditions that can worsen cases of the coronavirus may be found in roughly 1.7 billion people, as claimed by a new analysis.
Also Read: [COVID-19 Update] Early Results of Sinovac's Coronavirus Vaccine Show 90% of Trial Volunteers Developed Antibodies
On the other hand, a new coronavirus vaccine will be trialed by the Imperial College London. According to The Guardian's latest report, Imperial College London's researchers will begin testing the new coronavirus vaccine this week, which will be trialed in 300 people.
The researchers will inject two doses of vaccine to each of the healthy participants, aged between 18 and 17 years old. Once the vaccine was proven effective, the researchers hope it will be administered to 6,000 volunteers. Synthetic strands of genetic code based on the genetic materials of Sars-CoV-2 were used by Imperial College of London instead of using a weakened form of the illness.
"Is that protection against infection? Is it protection against illness? Is it protection against severe disease? It's quite possible a vaccine that only protects against severe disease would be very useful," said the Imperial College London professor leading vaccine's development, Robin Shattock, stating that early protective vaccines might not completely stop a person contracting the virus.
